Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer

• R. Escudero-Ávila ^[1] ; J. D. Rodríguez-Castaño ^[1] ; I. Osman ^[2] ; F. Fernandez ^[1] ; R. Medina ^[2] ; B. Vargas ^[3] ; M. Japón-Rodríguez ^[4] ; P. Sancho ^[1] ; B. Perez-Valderrama ^[1] ; J. M. Praena-Fernández ^[5] ; I. Duran ^[1]
  1. [1] Medical Oncology Department, Virgen del Rocío University Hospital
  2. [2] Urology Department, Virgen del Rocío University Hospital
  3. [3] Radiology Department, Virgen del Rocío University Hospital
  4. [4] Pathology Department, Virgen del Rocío University Hospital
  5. [5] Department of Statistics, FISEVI, Virgen del Rocío University Hospital

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 6, 2019, págs. 796-804
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Cancer-specific survival for patients with clinical stage I (CSI) germ cell testicular cancer (GCTC) is outstanding after inguinal orchidectomy regardless the treatment utilized. This study evaluated whether active surveillance (AS) of such patients yielded similar health outcomes to other therapeutic strategies such as adjuvant chemotherapy, radiotherapy or primary retroperitoneal lymphadenectomy as described in the literature.

    Patients and methods Patients with CSI GCTC were screened between January 2012 and December 2016. Patients had previously undergone inguinal orchidectomy as the primary treatment and chosen AS as their preferred management strategy after receiving information about all available strategies.

    Results Out of 91 patients screened, 82 patients selected AS as their preferred management strategy. Relapse rate in the overall population was 20% (95% CI 12–30) and median time to relapse was 11.5 months (range 1.0–35.0). In patients with seminomatous tumors, relapse rate decreased to 13% and median time to relapse was 13 months; whereas in patients with non-seminomatous tumors, relapse rate was 33% (IA) or 29% (IB) and median time to relapse was 12 months in stage IA and 4.5 months in stage IB patients. All relapses were rescued with three or four cycles of chemotherapy and two also required a retroperitoneal lymphadenectomy. All patients are currently alive and free of disease.

    Conclusions The clinical outcomes of patients with CSI GCTC managed by AS in this series were excellent. This strategy limited the administration of active treatments specifically to the minority of patients who relapsed without compromising performance.